Updated: Apr 7, 2021
on Cryotherapy Online Data Registry Outcomes: Minimum Five Year Follow up Data
Authors: David Levy*, Euclid, OH, Christopher Williams, Jacksonville, FL, Thomas Polascik, Durham, NC, Stephen Jones, Cleveland, OH Abstract: MP45-16 in 2014 AUA Convention in Orlando, Florida
Introduction and Objectives
We report a comprehensive update of 5 year COLD Registry outcomes for patients undergoing primary whole gland prostate cryoablation.
A risk stratified cohort of 1,111 treatment naïve patients who underwent primary whole gland cryoablation was identified. 5 year biochemical progression free Kaplan Meier survival curves were constructed based on Phoenix definition.
Overall bPFS* was: 79.9%, 64.1% and 68.1%, low, intermediate and high risk, respectively, (Figure 1).
For 817 (73.5%) patients with nadir PSA < 0.4 ng/ml, bPFS* was 91%, 80.5%, and 77.6%, low, intermediate and high risk, respectively.
Patients with a nadir PSA > 0.4 ng/ml demonstrated 24-month biochemical progression rates in excess of 34%.
Continence was preserved in 93.4% of patients, while 5.9% of patients had retention and 0.5% developed a rectal fistula.
Potency data entered into the Registry data base revealed that 35% of patients were potent at 12 months.
5 year bPFS* following prostate cryoablation is comparable to surgical and radiation outcomes across all risk categories with a lower likelihood of procedure related complications.
A nadir PSA > 0.4 ng/ml predicts a high likelihood of biochemical progression and warrants close follow up.
* bPFS: biochemical progression free survival Date & Time: May 18, 2014 3:30 PM-5:30 PM
Session Title: Prostate Cancer: Localized III Sources of Funding: none
Abstracts printed from AUA2014.org
Thank you for reading the post. Before you go, please leave your comment/suggest for improvement as well as helping others; I do appreciate it.